達西珠單抗
化合物
達西珠單抗（INN：dacetuzumab；開發代號：SGN-40或huS2C6）是一種人源化單株抗體，[1]正在開發用於治療CD40陽性癌症，如非霍奇金淋巴瘤[2]和血液惡性腫瘤。[3]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | CD40 |
| 臨床資料 | |
| 其他名稱 | SGN-40 |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 880486-59-9  |
| ChemSpider |
|
| UNII | |
| 化學資訊 | |
| 化學式 | C6452H9964N1732O1998S42 |
| 摩爾質量 | 145,111.33 g·mol−1 |
參考資料
編輯- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab （頁面存檔備份，存於互聯網檔案館）, American Medical Association.
- ^ Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. Journal of Clinical Oncology. September 2009, 27 (26): 4371–7. PMID 19636010. doi:10.1200/JCO.2008.21.3017
.
- ^ Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current Opinion in Investigational Drugs. June 2009, 10 (6): 579–87. PMID 19513947.
- ^ Khubchandani, Sapna; Czuczman, Myron S.; Hernandez-Ilizaliturri, Francisco J. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current Opinion in Investigational Drugs (London, England: 2000). 2009-06, 10 (6) [2024-03-10]. ISSN 2040-3429. PMID 19513947. （原始內容存檔於2024-03-10）.
